Vaxiion Therapeutics Initiates Phase 1 Clinical Trial of VAX014 for the Treatment of Non-Muscle Invasive Bladder Cancer in the United States

SAN DIEGO, CA, USA I April 18, 2019 I Vaxiion Therapeutics, the industry leader in bacterial minicell-based targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug application (IND) for VAX014, and the company will now initiate a Phase 1 clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC). VAX014 is a first-in-class recombinant bacterial minicell-based oncolytic immunotherapy that is engineered to selectively target a pair of NMIBC-associated cell-surface integrin heterodimers.

The study is a multi-center open label dose escalation with dose expansion Phase 1 trial evaluating the safety, tolerability, and initial anti-tumor activity in patients with NMIBC.

“Advancing our first product candidate into clinical trials is a major milestone, signifying Vaxiion’s transition to a clinical stage company,” said Vaxiion President, Matthew Giacalone. “We are now one step closer to achieving our ultimate goal of filling the unmet needs existing in the gaps of the current non-muscle invasive bladder cancer treatment algorithm.”

In preclinical models of NMIBC and other cancer types, VAX014 has repeatedly demonstrated durable anti-tumor immunotherapeutic activity resulting in complete tumor regressions and the development of long-term anti-tumor immunologic memory. In nonclinical safety studies, VAX014 was well tolerated following repeat dose administration in the clinically relevant dose range.

This first-in-human Phase 1 study will consist of two segments: a dose escalation segment and a dose expansion segment. Additional information about the trial can be found at

VAX014 is the first clinical product candidate generated from Vaxiion’s proprietary recombinant bacterial-minicell delivery platform.

About Vaxiion

Vaxiion Therapeutics is a clinical stage San Diego-based biotechnology company. Leveraging its closely related pair of proprietary first-in-class bacterial minicell-based delivery platforms, Vaxiion is developing and advancing novel, next generation oncology products. For more information about Vaxiion Therapeutics, please visit

SOURCE: Vaxiion Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up